» Articles » PMID: 17047148

Acquired Hemophilia A in the United Kingdom: a 2-year National Surveillance Study by the United Kingdom Haemophilia Centre Doctors' Organisation

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2006 Oct 19
PMID 17047148
Citations 215
Authors
Affiliations
Soon will be listed here.
Abstract

Acquired hemophilia A is a severe bleeding disorder caused by an autoantibody to factor VIII. Previous reports have focused on referral center patients and it is unclear whether these findings are generally applicable. To improve understanding of the disease, a 2-year observational study was established to identify and characterize the presenting features and outcome of all patients with acquired hemophilia A in the United Kingdom. This allowed a consecutive cohort of patients, unbiased by referral or reporting practice, to be studied. A total of 172 patients with a median age of 78 years were identified, an incidence of 1.48/million/y. The cohort was significantly older than previously reported series, but bleeding manifestations and underlying diseases were similar. Bleeding was the cause of death in 9% of the cohort and remained a risk until the inhibitor had been eradicated. There was no difference in inhibitor eradication or mortality between patients treated with steroids alone and a combination of steroids and cytotoxic agents. Relapse of the inhibitor was observed in 20% of the patients who had attained first complete remission. The data provide the most complete description of acquired hemophilia A available and are applicable to patients presenting to all centers.

Citing Articles

Real-World Data on Patients With Acquired Haemophilia A in Japan Undergoing Rehabilitation or With Low Activities of Daily Living Scores: The ORIHIME II Study.

Ogawa Y, Amano K, Sugao Y, Nosaka D, Murakami Y, Adachi H Haemophilia. 2024; 31(1):99-107.

PMID: 39692331 PMC: 11780186. DOI: 10.1111/hae.15132.


Outcomes of Emicizumab in Acquired Hemophilia Patients: A Systematic Review.

Ikbel G, Hela B, Yassine K, Hamida K, Kamel B Clin Appl Thromb Hemost. 2024; 30:10760296241298661.

PMID: 39543979 PMC: 11565686. DOI: 10.1177/10760296241298661.


Large Cell Neuroendocrine Carcinoma With Acquired Hemophilia A Diagnosed by Endobronchial Biopsy: A Case Report.

Yaoita K, Takasaki T, Ito S, Kawahata T, Maemondo M Cureus. 2024; 16(10):e70623.

PMID: 39483578 PMC: 11526768. DOI: 10.7759/cureus.70623.


Role of the Hemostasis and Thrombosis Unit in the Management of Patients with Acquired Hemophilia A.

Mameli A, Marongiu F, Fenu L, Ruberto M, Schirru P, Cornacchini S Turk J Haematol. 2024; 41(4):264-270.

PMID: 39463022 PMC: 11628764. DOI: 10.4274/tjh.galenos.2024.2024.0230.


Comorbidity and adverse events in acquired hemophilia A: data from the GTH-AHA-EMI study.

Burgmann C, Sachs U, Trautmann-Grill K, Pfrepper C, Knobl P, Greil R Res Pract Thromb Haemost. 2024; 8(7):102565.

PMID: 39420971 PMC: 11480235. DOI: 10.1016/j.rpth.2024.102565.